Hengrui Medicine repurchases 203,600 shares: Hengrui Medicine stock buyback costs CNY 9.40 million

Published on 10/20/2026 at 01:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hengrui Medicine bought 203,600 shares for CNY 9.40 million on October 19, 2026. Results due October 27 give Hengrui Medicine stock a catalyst.

Regulatory milestones

Hengrui Medicine repurchased 203,600 A-shares for CNY 9.40 million on October 19, 2026.
The EMA filing involved 496 patients, with median progression-free survival of 24.8 months versus 19.9 months.
The board is scheduled to review nine-month results on October 27, 2026.

Bank of Shanghai, CNE0000014W7, Illustration mit AI erstellt.

Hengrui Medicine (ISIN CNE0000014W7) repurchased 203,600 A-shares for CNY 9.40 million on October 19, 2026, according to Futu. The transaction puts the companys capital-return program alongside regulatory progress and an upcoming results date.

Buyback adds a cash signal

The October 19 purchase covered shares at CNY 46.08 to CNY 46.21 each, with the total consideration stated as CNY 9.4008 million by Futu. The reported purchase price was below the companys CNY 67.00 target cited in an October 2 report, but the two figures belong to different purposes and markets.

Chronology shows three measurable developments. On October 2, BofA Securities raised its A-share target from RMB 65.80 to RMB 67.00 and maintained a Buy rating, as reported by Futu. On October 8, Hengrui announced EMA validation for its fuzuloparib application, citing 496 trial participants and median progression-free survival of 24.8 months versus 19.9 months.

What does the filing mean for growth?

The EMA milestone gives the pipeline a second quantified reference beyond the buyback. Hengrui said the phase 3 trial covered 132 sites worldwide, while the trial result showed a hazard ratio of 0.71, according to the company release dated October 8, 2026.

Which date comes next?

The next dated event is October 27, 2026, when the board is scheduled to consider results for the nine months ended September 30, 2026, according to Futu. That report will provide the next company-specific test for whether regulatory activity and capital allocation are translating into operating progress.

Shanghai listing keeps the market frame

Hengrui Medicine is listed in Shanghai under ticker 600276.SS and ISIN CNE0000014W7. The last quoted price was CNY 46.08 on October 19, 2026 at 3:00 p.m. CST on the Shanghai market, with the session closed. Its market capitalization was CNY 293.9 billion, and the 52-week range was CNY 41.89 to CNY 67.85.